Heterocyclic Compounds

Matches 51 - 100 out of 12,018	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/050370A1	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
WO/2024/046223A1	INDAZOLE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF The present application relates to substituted indazole formamide derivatives, a preparation method therefor, and the use of a pharmaceutical composition containing the derivatives or deuterated derivatives in medicines. Specifically, th...
WO/2024/046512A2	NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The present invention relates to a nitrogen-containing macrocyclic compound, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a nitrogen-containing macrocyclic compound represe...
WO/2024/046409A1	HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
WO/2024/046361A1	AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or conditions related to the activity of RIPK1 kinase.
WO/2024/041628A1	DIARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a diaryl compound, a preparation method therefor, and use thereof. The diaryl compound of the present invention is a compound represented by formula I, a tautomer thereof, a stereoisomer thereof, a hydrate thereof, a solvat...
WO/2024/043341A1	CYCLOALKYNE DERIVATIVE The present invention provides a novel strain-promoted azide-alkyne cycloaddition (SPAAC) reaction. The present invention also provides a novel cycloalkyne derivative having a spiro ring as a cycloalkyne derivative that can be used in SP...
WO/2024/044713A1	NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
WO/2024/044344A1	PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/041079A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS The present application relates to an organic compound, an organic electroluminescent device, and an electronic apparatus. The organic compound provided by the present application has a structure as represented by formula (1). The organi...
WO/2024/041573A1	FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D or other KRAS mutants, and their uses.
WO/2024/043741A1	AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention relates to a novel compound for the inhibition of autotaxin, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing s...
WO/2024/040190A1	INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
WO/2024/039886A1	BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with ce...
WO/2024/040131A1	PYRIDOPYRIMIDINE KRAS INHIBITORS This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a), (I-aa), (I-b), (I-bb), (I-c), (I-cc), (I-d), (I-dd), (I-e), (I-ee), (I-f), (I-g), or (I-h)), Formula (II) (e.g., (II-c), (II-cc), (II-d), (II-dd),...
WO/2024/037616A1	COMPOUND CONTAINING CYCLOHEXYL The present application relates to a compound containing cyclohexyl, in particular to a compound of formula (I-AA), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition c...
WO/2024/040109A2	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/032755A1	COMPOUNDS AS BCL-2 INHIBITORS Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
WO/2024/033277A1	NEW HETEROCYCLIC COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...
WO/2024/032747A1	TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF The present application relates to tricyclic compounds and medical use thereof. The structure is represented by formula (I). Specifically, the present application further relates to a preparation method for the compounds, a pharmaceutica...
WO/2024/032704A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating the activity of KRAS G12D and/or G12V.
WO/2024/033454A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein A1 to A7and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2024/032702A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
WO/2024/032703A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
WO/2024/032776A1	COMPOUNDS AS BCL-2 INHIBITORS Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
WO/2024/032390A1	MACROCYCLIC TRIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a macrocyclic triazole compound represented by formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt, or a ...
WO/2024/027631A1	CRYSTAL FORM OF FUSED TRICYCLIC DERIVATIVE AND PREPARATION METHOD The present disclosure relates to a crystal form of a fused tricyclic derivative and a preparation method, and specifically relates to a crystal form of a compound (3S,4R)-4-((5-chloro-4-((S)-8-fluoro-2-(2-hydroxypropane-2-y l)-3-methyl-...
WO/2024/031088A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
WO/2024/027814A1	COMPOUND HAVING KRAS G12D INHIBITORY EFFECT Disclosed are a compound as represented by formula (I) having a KRas G12D inhibitory effect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the use thereof in the preparation of a drug for KRas G12D-related...
WO/2024/025817A1	SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5- DIHYDRO-2H-PYRIDO[3,4-F][L,4]OXAZEPINE-9-CARBONITRILE Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...
WO/2024/023284A1	NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
WO/2024/022167A1	CAMPTOTHECIN DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...
WO/2024/022435A1	CRYSTAL FORM OF 5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPINE COMPOUND AND PREPARATION METHOD THEREFOR Disclosed are a crystal form of a 5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine compound, a preparation method therefor, and the use of the crystal form in the preparation of a medicament for treating relevant diseases. Specifically di...
WO/2024/022444A1	FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF The present disclosure relates to a fused ring compound, a preparation method therefor and a medicinal application thereof. Specifically, the present disclosure relates to a fused ring compound represented by general formula (IN), a prep...
WO/2024/022266A1	HETEROARYL COMPOUNDS AS INHIBITORS OF USP1 The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...
WO/2024/022286A1	MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF The present invention relates to a macrocyclic EGFR inhibitor and a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an EGFR inhibitor having a structure of formula (I), a ph...
WO/2024/020517A1	3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITR ILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
WO/2024/020380A1	QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
WO/2024/017392A1	PYRIMIDINE RING COMPOUND, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Disclosed in the present invention are a pyrimidine ring compound, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof. The pyrimidine ring compound is a compound as represented by formula (I) or formula (II)...
WO/2024/016986A1	MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention relates to a macrocyclic inhibitor, a composition and a use thereof. In particular, the present invention relates to a compound as shown in formula (I), a pharmaceutical composition comprising the compound of the pr...
WO/2024/017380A1	TRICYCLIC-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF Disclosed in the present invention are a tricyclic-containing macrocyclic compound and a use thereof, and particularly disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.
WO/2024/017358A1	MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF The present invention relates to a macrocyclic inhibitor, a composition, and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a pharmaceutical composition containing said compound, and...
WO/2024/020068A1	BACTERIAL TOPOISOMERASE INHIBITORS Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...
WO/2024/017251A1	MACROCYCLE FOR INHIBITING AND INDUCING EGFR DEGRADATION AND PREPARATION METHOD FOR AND USE OF MACROCYCLE The present disclosure relates to a macrocycle for inhibiting and inducing EGFR degradation and a preparation method for and a use of the macrocycle. Specifically, the present disclosure relates to a macrocycle as shown in general formul...
WO/2024/017258A1	EGFR SMALL MOLECULE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Disclosed in the present invention are a multi-target small molecule inhibitor, a pharmaceutical composition containing same, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I)....
WO/2024/017857A1	NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/015340A1	CEREBLON LIGANDS AND USES THEREOF Described herein are compounds or conjugates of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading ce...
WO/2024/015346A1	CEREBLON LIGANDS AND USES THEREOF Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for ce...
WO/2024/015497A1	TYROSINE KINASE 2 INHIBITORS AND USES THEREOF This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...
WO/2024/015406A1	INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).

Matches 51 - 100 out of 12,018	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >